<DOC>
	<DOC>NCT00326963</DOC>
	<brief_summary>This single arm study will evaluate the efficacy, safety and tolerability of a new investigational protease inhibitor (PI) plus background antiretrovirals plus Fuzeon (90mg sc bid) in HIV-1 infected, triple-class treatment-experienced, Fuzeon-naive adults. The new investigational PI will be administered according to the procedures of the early access program in which the patient is enrolled. The anticipated time on study treatment is 3-12 months, and the target sample size is approximately 120 individuals.</brief_summary>
	<brief_title>BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; seropositive for HIV1; enrolled in an early access program for a new investigational PI; naive to Fuzeon, and the investigational PI; treatmentexperienced with 3 ARV classes of drug (NRTI, NNRTI and PI). females who are pregnant or breastfeeding; evidence of active, untreated opportunistic infection; malignancy requiring chemotherapy or radiotherapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>